PRTC

NEUTRAL

$18.3 Live

PureTech Health plc · NASDAQ

$14.5 52W Range $19.92

PRTC PureTech Health plc - Fundamental Analysis

NEUTRAL

Console Chart News

PRTC Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Biotechnology

Current Price Live

$18.3

52W High

$19.92

52W Low

$14.5

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 18, 2026

Market cap

$445.46M

P/E

10.7

ROE

9.4%

Profit margin

793.0%

Debt/Equity

0.44

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

75%

PRTC presents a contradictory financial profile with a stable Piotroski F-Score of 5/9 and a strong liquidity position (Current Ratio 8.49), yet suffers from severe operational inefficiency. While the Graham Number of $24.47 suggests defensive value, the growth-based intrinsic value of $11.90 and a negative forward P/E indicate significant future earnings risk. The massive discrepancy between the reported profit margin (792.96%) and operating margin (-2589.52%) suggests the company is relying on non-operating gains rather than core business profitability. Short-term price momentum is positive, but long-term performance remains deeply depressed.

Key Strengths

Exceptional short-term liquidity with a Current Ratio of 8.49

Low leverage with a Debt/Equity ratio of 0.44

Explosive year-over-year revenue growth of 542.70%

Low Price-to-Book ratio (1.17) suggesting asset-backed valuation

Strong short-term price momentum (+12.6% in the last month)

Key Risks

Catastrophic operating margins (-2589.52%) indicating high cash burn

Negative forward P/E suggests expected losses in the coming year

Extremely high Price-to-Sales ratio (69.70) indicating overvaluation relative to revenue

Severe long-term price erosion (-68.3% over 5 years)

Lack of analyst coverage and institutional guidance

AI Fair Value Estimate

Based on comprehensive analysis

$15.5

-15.3% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

Speculative Hold

Key drivers: High liquidity, Operational losses, Revenue growth, Accounting anomalies

Confidence

80%

Value

55/100

P/E 10.70, Graham Number $24.47, Intrinsic $11.90

Positives

P/B ratio is low
Current price is below Graham Number

Watchpoints

P/S ratio is unsustainable
Intrinsic value is below current price

Future

40/100

Revenue Growth 542.70%, Forward P/E -36.60

Positives

Massive YoY revenue growth

Watchpoints

Negative forward P/E
High operational burn

Past

30/100

Long-term bearish trend despite short-term bounce

Positives

Recent 1-month recovery

Watchpoints

5-year return of -68.3%
3-year return of -33.5%

Health

70/100

Strong balance sheet but poor operational efficiency

Positives

Piotroski F-Score 5/9 (Stable)
Very high Current/Quick ratios
Low Debt/Equity

Watchpoints

Negative ROA

Dividend

0/100

Dividend Strength 0/100

Positives

No standout positives identified.

Watchpoints

No dividend paid

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$18.3

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for PRTC and closest competitors.

Updated 2026-04-17

Company	5Y	3Y	1Y	6M	1M	1W
PRTC PureTech Health plc Primary	-68.3%	-33.5%	+9.3%	+1.7%	+12.6%	+10.9%
ASMB Assembly Biosciences, Inc. Peer	-54.7%	+80.2%	+165.0%	+28.7%	+2.8%	-0.6%
ALT Altimmune, Inc. Peer	-80.3%	-68.4%	-32.7%	-3.9%	-24.4%	-1.1%
MYGN Myriad Genetics, Inc. Peer	-82.9%	-78.0%	-39.2%	-37.0%	+7.0%	+3.6%
ACRS Aclaris Therapeutics, Inc. Peer	-85.2%	-56.5%	+126.9%	+81.5%	+4.4%	+15.7%

PRT

PureTech Health plc

Primary

-68.3%

-33.5%

+9.3%

+1.7%

+12.6%

+10.9%

ASM

Assembly Biosciences, Inc.

Peer

-54.7%

+80.2%

+165.0%

+28.7%

+2.8%

-0.6%

ALT

Altimmune, Inc.

Peer

-80.3%

-68.4%

-32.7%

-3.9%

-24.4%

-1.1%

MYG

Myriad Genetics, Inc.

Peer

-82.9%

-78.0%

-39.2%

-37.0%

+7.0%

+3.6%

ACR

Aclaris Therapeutics, Inc.

Peer

-85.2%

-56.5%

+126.9%

+81.5%

+4.4%

+15.7%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

10.7

-36.6

N/A

1.17

69.7

660.62

-36.48

$445.46M

Profitability

Profit margins and return metrics

Profit Margin 792.96%

Operating Margin -2589.52%

Gross Margin N/A

ROE 9.44%

ROA -12.95%

Growth

Revenue and earnings growth rates

Revenue Growth +542.7%

Earnings Growth N/A

Q/Q Revenue Growth N/A

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.44

Low debt

Current Ratio

8.49

Strong

Quick Ratio

8.35

Excellent

Cash/Share

$1.38

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q2 2025

Total Assets

$0.6B

Liabilities

$0.2B

Equity

$0.4B

Debt/Equity

0.49x

Quarterly Earnings History

EPS performance vs analyst estimates

2026-04-29

$N/A

Healthcare Sector Comparison

Comparing PRTC against 418 companies in the Healthcare sector (24 bullish, 134 neutral, 260 bearish)

P/E Ratio

10.7

This Stock

89.67

Sector Avg

-88.1% (Discount)

Return on Equity (ROE)

9.44%

This Stock

-101.05%

Sector Avg

-109.3% (Below Avg)

Profit Margin

792.96%

This Stock

-13.75%

Sector Avg

-5865.9% (Weaker)

Debt to Equity

0.44

This Stock

3.24

Sector Avg

-86.3% (Less Debt)

Revenue Growth

542.7%

This Stock

121.5%

Sector Avg

+346.7% (Fast Growth)

Current Ratio

8.49

This Stock

4.55

Sector Avg

+86.4% (Stronger)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
PRTC PureTech Health plc	NEUTRAL	$445.46M	10.7	9.4%	793.0%	$18.3
ASMB Assembly Biosciences, Inc.	NEUTRAL	$444.7M	-	-36.9%	-103.6%	$28.11	Compare
ALT Altimmune, Inc.	BEARISH	$438.31M	-	-50.6%	-%	$3.5	Compare
MYGN Myriad Genetics, Inc.	BEARISH	$459.13M	-	-23.5%	-41.3%	$4.91	Compare
ACRS Aclaris Therapeutics, Inc.	BEARISH	$428.65M	-	-50.2%	-%	$3.54	Compare

PRTC PureTech Health plc

NEUTRAL

Mkt Cap

$445M

P/E

10.7

ROE

9.4%

Price

$18.3

Compare with PRTC

Compare with PRTC

MYGN Myriad Genetics, Inc.

Compare with PRTC

Compare with PRTC

SEC Filings

Recent regulatory filings from the SEC EDGAR database

20-F

2025-04-30

PRTC filed its annual report on Form 20-F on April 30, 2025. Due to the absence of provided excerpts, specific financial highlights and risk factors cannot be detailed at this time.

20-F

2024-04-25

PRTC filed its 20-F annual report on April 25, 2024, providing a comprehensive overview of its fiscal year operations and financial condition. Specific financial highlights and risk factors are detailed within the full filing.

Data sourced from SEC EDGAR. AI summaries generated automatically.

Past News Coverage

Recent headlines mentioning PRTC from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

PRTC

PRTC PureTech Health plc - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

SEC Filings

Past News Coverage

Wait — Don't Miss Out!